CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 31 enrolled
Drug / intervention
Omega-3 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01686568
NCT01686568Phase 3Completed
CompareCT.gov

Dietary Omega-3 Fatty Acids as a Therapeutic Strategy in Insulin Resistant Humans

Mayo Clinic·interventional·Posted Sep 18, 2012·Updated Mar 3, 2017

In Brief

A Phase 3 clinical trial evaluating Omega-3 and placebo for Insulin Resistance. Completed, enrolled 31 participants across 1 site.

Detailed Summary

This study is being done to understand the effects of dietary omega-3 fats on insulin sensitivity in adult men and women.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInsulin Resistance
CountriesUnited States
CollaboratorsNational Center for Advancing Translational Sciences (NCATS), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Building Interdisciplinary Research Careers in Women's Health

Timeline

Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedSep 18, 2012
Enrollment StartDec 21, 2012
Primary CompletionOct 30, 2014
Study CompletionJun 8, 2015
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 13.8 years ago

Interventions

Omega-3drug

Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.

placebodrug